logo.png
Nexstim Receives an NBT® System Order from a New Therapy Customer in Finland
29 avr. 2021 03h00 HE | Nexstim Oyj
Press Release, Helsinki, 29 April 2021 at 10:00 AM (EEST) Nexstim Receives an NBT® System Order from a New Therapy Customer in Finland Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company")...
axsomelogo-468x57.jpg
Axsome Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for AXS-05 for Treatment of Major Depressive Disorder
26 avr. 2021 06h00 HE | Axsome Therapeutics, Inc.
FDA grants Priority Review and sets PDUFA action goal date of August 22, 2021 NEW YORK, April 26, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company...
logo.png
Nexstim Plc Business and Clinical Update Q1 2021
22 avr. 2021 05h00 HE | Nexstim Oyj
Press release, Helsinki, 22.04.2021, 12.00 pm (EEST) Nexstim Plc Business and Clinical Update Q1 2021 Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces the key highlights of...
logo.png
Nexstim Receives Positive Feedback from Mind Matters Psychiatry MD on Use of Their Two NBT® Systems to Treat MDD
16 avr. 2021 05h00 HE | Nexstim Oyj
Press release, Helsinki, 16.04.2021, 12.00 pm (EEST) Nexstim Receives Positive Feedback from Mind Matters Psychiatry MD on Use of Their Two NBT® Systems to Treat MDD Nexstim Plc (NXTMH:HEX,...
compass_positive_tagline-01.png
New England Journal of Medicine publishes exploratory study showing signals of positive activity in COMP360 psilocybin compared with escitalopram for major depressive disorder
15 avr. 2021 03h00 HE | COMPASS Pathfinder Ltd.
London, UK, April 15, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in...
New Novel Depicts the Life of a Modern-Day Everyman as He Navigates Anxiety, Disenchantment and Loss
22 mars 2021 09h00 HE | Archway Publishing
SAVANNAH, Ga., March 22, 2021 (GLOBE NEWSWIRE) -- According to the New York Times, along with the COVID-19 pandemic and quarantine came mental health struggles that have stemmed from many factors...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
17 mars 2021 07h00 HE | Praxis Precision Medicines, Inc.
PRAX-114 Phase 2/3 clinical trial for treatment of MDD to initiate in March 2021 following IND clearance PRAX-944 Phase 2a high dose cohort topline data expected in mid-year 2021 Innovative...
logo.png
Nexstim Gives an Update on its Promising Treatment Results of Major Depressive Disorder
12 mars 2021 03h00 HE | Nexstim Oyj
Press Release, Helsinki, 12 March 2021 at 10.00 (EET) Nexstim Gives an Update on its Promising Treatment Results of Major Depressive Disorder Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or...
Headstrong Project Inc., Announces Two-Year Investment from the Robert R. McCormick Foundation, Expanding Care to U.S. Veterans within Vulnerable Regions in Chicagoland Area
11 mars 2021 08h00 HE | The Headstrong Project
New York, NY, March 11, 2021 (GLOBE NEWSWIRE) -- Headstrong Project Inc., a national-facing mental health treatment practice providing veterans with barrier-free mental health care, received a...
Headstrong Project Inc. Announces Partnership with Wounded Warrior Project to Increase Mental Health Service Innovations for Veterans and Their Families
08 mars 2021 08h00 HE | The Headstrong Project
New York, NY, March 08, 2021 (GLOBE NEWSWIRE) -- Headstrong Project Inc., a national mental health treatment practice providing veterans with barrier-free mental health care, received a grant from...